Let me put you on the spot for a second. When you are searching for different stocks to buy, lets say penny stocks for now, what exactly are you looking for? Do you watch for chart patterns to emerge? Are you looking for specific technical indicators? Could it even be possible that you are watching Twitter for game-changing tweets or other social media for the same type of message?
You wouldn’t be wrong if you are doing any of the above. The important thing to understand is that you cannot be trading on intuition. You can’t trade on a hope and a prayer. Sure it might work out from time to time, but overall, you’re putting yourself in a bad spot to be consistent.
Read More: 3 Top Penny Stocks To Monitor This Moment
Let’s think about this simply. What’s something that excites an investor enough to get involved with buying a stock? For one, when a Biotech company issues a major press/news release, it can stir up some serious momentum for a stock as we’ve seen already this month. Below, I’ve uncovered a handful of Biotech penny stocks with recent news that has put their companies in the spotlight.
Your Top Biotech Penny Stock To Watch No. 1: Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.
Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform.
Navidea Biopharmaceuticals, Inc. recently announced positive preliminary results from the Company’s second interim analysis of its ongoing NAV3-31 Phase 2B study.
Analysis demonstrates that these interim data further corroborate Navidea’s hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis (“RA”), and that this imaging can provide an early indicator of treatment efficacy in patients with active RA.
Your Top Biotech Penny Stock To Watch No. 2: Seneca Biopharma, Inc.
Seneca Biopharma, Inc. (Nasdaq: SNCA), is a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need. The Company is in the process of transforming the organization through the acquisition or in-licensing of new science and technologies, to develop with the goal of providing meaningful therapies for patients.
NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, ALS, and chronic spinal cord injury (cSCI).
Seneca Biopharma announced last month that the company held a Type C meeting with the Office of Tissues and Advanced Therapies at the FDA on March 10, 2020 to discuss future clinical development plans for NSI-566, the company’s leading neural stem cell therapy candidate, for the treatment of patients with amyotrophic lateral sclerosis (ALS). As a result of the discussion and feedback received from the FDA, Seneca believes that the existing phase 1 and 2 trial results support moving into a phase 3 clinical study for ALS.
“This represents a major step forward in getting our potentially beneficial therapy to patients who suffer from this devastating disease,” said David Recker, M.D., Chief Medical Officer for Seneca. “We received significant guidance from FDA regarding an acceptable trial design and are in the process of developing the protocol for further review.”
Your Top Biotech Penny Stock To Watch No. 3: Celsion Corporation
Celsion Corporation (Nasdaq: CLSN) is a fully integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies.
The Company’s lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies.
In April 2020, the Company announced that the prescribed minimum number of events (158 patient deaths) was reached for the second pre-specified interim analysis of the OPTIMA Phase III Study with ThermoDox® plus RFA (radiofrequency ablation) in patients with HCC. Following preparation of the data, the Independent Data Monitoring Committee (iDMC) is expected to meet in July to conduct the second interim analysis. Celsion expects to announce iDMC recommendations as soon as possible after the meeting. The hazard ratio (HR) and p-value necessary for success at 158 deaths are 0.70 and 0.022, respectively, which compare favorably with the hazard ratio and p-value observed in the prospective HEAT Study subgroup upon which the OPTIMA Study is based.
The OPTIMA Study was fully enrolled in August 2018 with 556 subjects from 65 clinical sites in 14 countries. The study design is based on the Company’s HEAT Study, in which a prospective subgroup analysis of 285 subjects with a single lesion of 3-7 cm in size received a single ThermoDox® administration in combination with a 45 minute or longer RFA procedure. Followed prospectively for 3 years, those patients demonstrated a median survival of more than 7 ½ years and a survival benefit of more than 2 years over the control group.
